home / stock / optn / optn news

OPTN News and Press, OptiNose Inc. From 06/13/22

Stock Information
Company Name: OptiNose Inc.
Stock Symbol: OPTN
Market: NASDAQ
Website: optinose.com
Menu
OPTN OPTN Quote OPTN Short OPTN News OPTN Articles OPTN Message Board
Get OPTN Alerts

News, Short Squeeze, Breakout and More Instantly...
OPTN - BTCM, ANTE and CLNN among mid-day movers

Gainers: Day One Biopharmaceuticals (DAWN) +103%. Redbox Entertainment (RDBXW) +85%. OptiNose (OPTN) +37%. Cerberus Cyber Sentinel Corporation (CISO) +36%. Ekso Bionics Holdings (EKSO) +35%. AeroClean Technologies (AERC) +33%. Redbox Entertainment (RDBX) +29%. Electro-Sensors (ELSE) +17%. Cyn...
OPTN - Optinose climbs 36% on positive late-stage data for sinusitis candidate

OptiNose (NASDAQ:OPTN) added 36% in the morning hours Monday after the commercial-stage pharma company announced Phase 3 data to indicate that its FDA-approved therapy for nasal polyps, Xhance was effective in chronic sinusitis patients. A drug-device combination to deliver topical ...

OPTN - Day One Biopharmaceuticals leads healthcare gainers; ContraFect, SciSparc among losers

Gainers: Day One Biopharmaceuticals (DAWN) +111%. Ekso Bionics Holdings (EKSO) +22%. OptiNose (OPTN) +19%. Tivic Health Systems (TIVC) +10%. Belite Bio (BLTE) +7%. Losers: ContraFect (CFRX) -23%. Reviva Pharmaceuticals Holdings (RVPH) -20%. Neptune Wellness Solutions (NEPT) -19%. Sc...

OPTN - EDU, ME and ASTS among pre market gainers

Day One Biopharmaceuticals (DAWN) +81% announces positive initial data from pivotal FIREFLY-1 trial of Tovorafenib (DAY101) in relapsed pediatric low-grade Glioma. Redbox Entertainment (RDBX) +30%. Ekso Bionics Holdings (EKSO) +22% receives FDA clearance to market its EksoNR Robotic...
OPTN - Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps Indication and the...

OPTN - Optinose CFO Keith Goldan to depart

Specialty pharmaceutical company Optinose (NASDAQ:OPTN) has announced the departure of CFO Keith Goldan, effective June 10, 2022. Goldan has accepted a CFO opportunity at another public company. VP Finance Michele Janis will now serve as acting CFO, while Anthony Krick, Vice President, Contro...

OPTN - Optinose Announces Departure of Chief Financial Officer

Michele Janis Appointed Acting Chief Financial Officer Anthony Krick Appointed Vice President & Chief Accounting Officer YARDLEY, Pa., June 03, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and th...
OPTN - OptiNose, Inc. 2022 Q1 - Results - Earnings Call Presentation

The following slide deck was published by OptiNose, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: OptiNose, Inc. 2022 Q1 - Results - Earnings Call Presentation

OPTN - OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2022 Results - Earnings Call Transcript

OptiNose, Inc. (OPTN) Q1 2022 Earnings Conference Call May 12, 2022, 08:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Keith Goldan - CFO Vic Clavelli - Chief Commercial Officer Ramy Mahmoud - President and COO Conference Call Participants Stacey Ku - Cowen Dave Amsellem...

OPTN - OptiNose GAAP EPS of -$0.31, revenue of $14.76M; issues FY22 guidance

OptiNose press release (NASDAQ:OPTN): Q1 GAAP EPS of -$0.31. Revenue of $14.76M (+23.4% Y/Y). The Company had cash and cash equivalents of $91.4 million as of March 31, 2022. Corporate Guidance:  The Company expects XHANCE net revenues for the full year of 2022 to be at least $90 million...
Previous 10 Next 10